A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma

✍ Scribed by Thomas K. Eigentler; Anne Kamin; Benjamin M. Weide; Helmut Breuninger; Ulrich M. Caroli; Matthias Möhrle; Peter Radny; Claus Garbe

• Book ID: 116583248
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 702 KB
• Volume: 57
• Category: Article
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2007.05.022